UBS Group’s LYRA THERAPEUTICS INC LYRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-675
| Closed | -$2.08K | – | 10889 |
|
|
2025
Q4 | $2.08K | Sell |
675
-3,326
| -83% | -$16.5K | ﹤0.01% | 9386 |
|
|
2025
Q3 | $26.1K | Buy |
4,001
+3,999
| +199,950% | +$29.3K | ﹤0.01% | 7991 |
|
|
2025
Q2 | $18 | Sell |
2
-8,683
| -100% | -$72K | ﹤0.01% | 10126 |
|
|
2025
Q1 | $54.7K | Buy |
8,685
+186
| +2% | +$1.74K | ﹤0.01% | 7518 |
|
|
2024
Q4 | $87.5K | Buy |
8,499
+8,001
| +1,607% | +$88K | ﹤0.01% | 6961 |
|
|
2024
Q3 | $6.4K | Buy |
498
+204
| +69% | +$3K | ﹤0.01% | 7973 |
|
|
2024
Q2 | $4.07K | Buy |
+294
| New | +$33.2K | ﹤0.01% | 8133 |
|
|
2024
Q1 | – | Sell |
-96
| Closed | -$25.6K | – | 8823 |
|
|
2023
Q4 | $25.2K | Buy |
+96
| New | +$17.4K | ﹤0.01% | 6959 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 8954 |
|
|
2023
Q2 | – | Sell |
-17
| Closed | -$2.36K | – | 8551 |
|
|
2023
Q1 | $1.71K | Sell |
17
-51
| -75% | -$6.32K | ﹤0.01% | 8665 |
|
|
2022
Q4 | $10.7K | Buy |
68
+6
| +10% | +$1.19K | ﹤0.01% | 8480 |
|
|
2022
Q3 | $15K | Buy |
62
+22
| +55% | +$6.51K | ﹤0.01% | 7809 |
|
|
2022
Q2 | $11K | Buy |
+40
| New | +$10.9K | ﹤0.01% | 7824 |
|
|
2022
Q1 | – | Sell |
-81
| Closed | -$17.8K | – | 10625 |
|
|
2021
Q4 | $18K | Buy |
+81
| New | +$26K | ﹤0.01% | 7979 |
|
|
2021
Q3 | – | Sell |
-11
| Closed | -$4.16K | – | 9844 |
|
|
2021
Q2 | $5K | Sell |
11
-44
| -80% | -$20K | ﹤0.01% | 8552 |
|
|
2021
Q1 | $32K | Sell |
55
-17
| -24% | -$10.6K | ﹤0.01% | 6957 |
|
|
2020
Q4 | $41K | Buy |
72
+55
| +324% | +$31K | ﹤0.01% | 6360 |
|
|
2020
Q3 | $9K | Sell |
17
-17
| -50% | -$10.6K | ﹤0.01% | 6938 |
|
|
2020
Q2 | $19K | Buy |
+34
| New | +$24.9K | ﹤0.01% | 6589 |
|
Other funds holding LYRA
UBS Group's LYRA Position: Q1 2026 in Review
UBS Group sold out of LYRA THERAPEUTICS INC (LYRA) in Q1 2026, closing a stake of 675 shares — an estimated $2.08K sold.
UBS Group first reported a position in LYRA in Q2 2020 and held it in 18 quarters. The position peaked at $87.5K in Q4 2024. 1 fund tracked by Wall St. Rank holds LYRA as of Q1 2026.
- UBS Group reported no remaining LYRA THERAPEUTICS INC position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 675 LYRA THERAPEUTICS INC shares in Q1 2026, an estimated $2.08K.
- UBS Group first reported a position in LYRA THERAPEUTICS INC in Q2 2020 and held it in 18 quarters.
- UBS Group's LYRA THERAPEUTICS INC position peaked at $87.5K in Q4 2024.
- 1 fund tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.